Randy Dockens - Concepedia

Author

Randy Dockens

Bristol-Myers Squibb (United States)

Also Known As

R DOCKENS, R Dockens, R. C. DOCKENS, R. C. Dockens, Randy C Dockens, Randy C. Dockens, Randy Dockens

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Germany)Bristol-Myers Squibb (Sweden)Bioanalytical Systems (United States)Bristol-Myers Squibb (United Kingdom)

About

Randy Dockens is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	451
2	Biochemistry	2	2	118
3	Health Sciences	1	1	10
4	Natural Sciences	1	1	80
5	Emergency Medicine	1	1	16

Randy Dockens

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease Vladimir Coric, Christopher H. van Dyck, Stephen Salloway, Archives of Neurology	2012	363
Targeting Prodromal Alzheimer Disease With Avagacestat Vladimir Coric, Stephen Salloway, Christopher H. van Dyck, JAMA Neurology	2015	229
Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder Vladimir Coric, Howard Feldman, Dan A. Oren, Depression and Anxiety	2010	171
Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Seth Sweetser, Michael Camilleri, Sara J. Linker Nord, American Journal of Physiology-Gastrointestinal and Liver Physiology InflammationGastrointestinal Peptide HormoneFunctional Gastrointestinal DisorderGastrointestinal PharmacologyMedicine	2009	114
Anticonvulsant activity of some 4-aminobenzamides Charles R. Clark, Martha J.M. Wells, Ricky T. Sansom, Journal of Medicinal Chemistry Second Aromatic RingAntiparasitic AgentPharmacotherapyMedicinal ChemistryPharmacological Study	1984	80
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of the Oral γ-Secretase Inhibitor BMS-708163 (Avagacestat): Tolerability Profile, Pharmacokinetic Parameters, and Pharmacodynamic Markers Gary Tong, Junsheng Wang, Oleksandr Sverdlov, Clinical Therapeutics Single-ascending Dose StudyTherapeutic Drug MonitoringPharmacologyClinical TrialsPharmacokinetic Parameters	2012	65
Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat Charles F. Albright, Randy Dockens, Jere E. Meredith, Journal of Pharmacology and Experimental Therapeutics	2012	63
Coadministration of Nefazodone and Benzodiazepines Douglas S. Greene, Daniel E. Salazar, Randy Dockens, Journal of Clinical Psychopharmacology	1995	61
Pharmacokinetics and Tolerability of Buspirone during Oral Administration to Children and Adolescents with Anxiety Disorder and Normal Healthy Adults Daniel E. Salazar, Edyta J. Frackiewicz, Randy Dockens, The Journal of Clinical Pharmacology	2001	48
A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects Randy Dockens, Junsheng Wang, Lorna Castaneda, Clinical Pharmacokinetics Drug SafetyPharmacological StudyElderly SubjectsPharmacologyClinical Trials	2012	47

Page 1